FDA says Botanical Be sold three pain products containing hidden diclofenac, an unapproved drug, and made drug claims.
What happened
FDA reviewed Botanical Be's website in July 2023 and obtained samples and labeling of Kuka Flex Forte, Reumo Flex, and Artri King Reforzado con Ortiga y Omega 3. Laboratory analysis confirmed the products contain undeclared diclofenac, an NSAID (non-steroidal anti-inflammatory drug). FDA says the products are unapproved new drugs and misbranded (labeling is false or misleading) because the labeling does not disclose diclofenac.
What FDA found
The products are unapproved new drugs because they are not generally recognized as safe and effective and have no FDA-approved application.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The labeling is misleading because it does not reveal that the products contain diclofenac.
FD&C Act section 502(a), 21 U.S.C. 352(a); section 201(n), 21 U.S.C. 321(n)Selling these misbranded drugs in interstate commerce is a prohibited act.
FD&C Act section 301(a), 21 U.S.C. 331(a)Kuka Flex Forte and Reumo Flex are outside the dietary supplement definition because diclofenac was approved as a drug before it was marketed as a supplement.
FD&C Act sections 201(ff)(3)(B)(i) and (ii), 21 U.S.C. 321(ff)(3)(B)(i) and (ii)
What FDA wants
FDA asks Botanical Be to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with supporting documents. If correction cannot be completed, the company must explain the delay and when it will finish.
Who should pay attention
- retailers and online marketplaces selling pain or arthritis products
- brands that buy or distribute imported supplements
- consumers using NSAIDs or arthritis pain products
This is a summary. Read the original letter on fda.gov.